Pharmacokinetic Properties and Systemic Safety of Vancomycin-Impregnated Cancellous Bone Grafts in the Treatment of Spondylodiscitis
Table 1
Demographic data, microbiological findings, and treatment information of 8 patients suffering from a spondylodiscitis and being treated with vancomycin-loaded, cancellous bone grafts.
Patient
1
2
3
4
5
6
7
8
Age/gender
73/F
65/M
61/M
73/F
75/F
83/F
77/F
43/M
Spondylodiscitis localization
L3/4
L4/5
Th 6/7
Th 8/9
L3/4
L2/3
Th12/L1
Th10-11
Pathogen organism
n.o.i.
S. hominis
S. epidermidis
E. cloacae
MRSA
E. coli
n.o.i.
S. aureus
Surgical therapy
One-stage anterior-posterior stabilization
One-stage anterior-posterior stabilization
Two-stage anterior-posterior stabilization
One-stage anterior-posterior stabilization
Two-stage anterior-posterior stabilization
One-stage anterior-posterior stabilization
Two-stage anterior-posterior stabilization
One-stage anterior-posterior stabilization
Implant used
VLIFT + AIBGs
AIBGs
VLIFT + AIBGs
VLIFT + AIBGs
AIBGs
AIBGs
AIBGs
VLIFT + AIBGs
Intravenous antibiotic therapy
Meronem + daptomycin
Levofloxacin
Cefuroxime + rifampicin
Ceftazidime + refobacin
Rifampicin + daptomycin
Cefotaxime
Clindamycin
Cefuroxime
Oral antibiotic therapy
Levofloxacin
Levofloxacin
Linezolid
Levofloxacin
Linezolid
Ciprofloxacine
Ciprofloxacine
Cefuroxime
Follow-up [months]
13
27
16
12
36
12
12
4
M: male; F: female; n.o.i.: no organism isolated; AIBGs: antibiotic-impregnated bone graft; MRSA: methicillin-resistant Staphylococcus aureus.